Zobair Younossi, MD

Articles by Zobair Younossi, MD

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

ByNaoky Tsai, MD,Bruce Bacon, MD,Michael Curry, MD,Steven L. Flamm, MD,Scott Milligan, PhD,Nicole Wick, AS,Zobair Younossi, MD,Nezam Afdhal, MD

July 12th 2019

From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

ByZobair Younossi, MD,Stuart C. Gordon, MD,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD,Rachel Beckerman, PhD

February 16th 2017

Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

Latest Updated Articles

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact
February 16th 2017
Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017
July 12th 2019

Zobair Younossi, MD

Articles by Zobair Younossi, MD

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care